Alliance for Regenerative Medicine Annual Report Highlights Record Sector Growth and Resilience in 2020 ALLIANCE FOR REGENERATIVE MEDICINE ANNUAL REPORT HIGHLIGHTS RECORD SECTOR GROWTH AND RESILIENCE IN 2020 Sector financing reached $19.9B in 2020, doubling from the previous year; 2021 is likely to be a record year for the number of regulatory decisions on new ATMPs BRUSSELS, Belgium – March 16, 2020 The regenerative medicine and advanced therapies sector raised a record $19.9B in funding in 2020, fueling the broader biotech sector and driving a rapidly advancing pipeline of potentially transformative therapies, according to the Alliance for Regenerative Medicine’s (ARM) Two new therapies received approval in 2020: Orchard Therapeutics’ gene therapy Libmeldy, by the European Medicines Agency (EMA), and Kite’s Tecartus chimeric antigen receptor T-cell (CAR-T) therapy, by the Food & Drug Administration (FDA). By the end of 2020, there were 152 ongoing Phase 3 trials worldwide in cell, gene, and tissue-based therapies. Regulatory decisions are expected on a record eight new Advanced Therapy Medicinal Products (ATMPs) – and on a total of ten products across at least four geographies -- in 2021, including Breyanzi, a Bristol Myers Squibb CAR-T therapy for relapsed or refractory large B-cell lymphoma that already received FDA approval in February.